Biosolution Co.Ltd - Asset Resilience Ratio
Biosolution Co.Ltd (086820) has an Asset Resilience Ratio of 0.34% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Biosolution Co.Ltd's Asset Resilience Ratio has changed over time. Check 086820 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Biosolution Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Biosolution Co.Ltd (086820) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩211.66 Million | 0.34% |
| Total Liquid Assets | ₩211.66 Million | 0.34% |
Asset Resilience Insights
- Limited Liquidity: Biosolution Co.Ltd maintains only 0.34% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Biosolution Co.Ltd Industry Peers by Asset Resilience Ratio
Compare Biosolution Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX |
Biotechnology | 46.79% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 63.47% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Biosolution Co.Ltd (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Biosolution Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 21.27% | ₩14.35 Billion ≈ $9.72 Million |
₩67.46 Billion ≈ $45.72 Million |
-19.56pp |
| 2023-12-31 | 40.83% | ₩37.71 Billion ≈ $25.56 Million |
₩92.35 Billion ≈ $62.58 Million |
-38.53pp |
| 2022-12-31 | 79.36% | ₩72.80 Billion ≈ $49.34 Million |
₩91.73 Billion ≈ $62.16 Million |
-8.65pp |
| 2021-12-31 | 88.01% | ₩83.08 Billion ≈ $56.30 Million |
₩94.40 Billion ≈ $63.98 Million |
+15.31pp |
| 2020-12-31 | 72.70% | ₩36.20 Billion ≈ $24.54 Million |
₩49.80 Billion ≈ $33.75 Million |
-5.43pp |
| 2019-12-31 | 78.13% | ₩40.48 Billion ≈ $27.43 Million |
₩51.81 Billion ≈ $35.11 Million |
-6.71pp |
| 2018-12-31 | 84.85% | ₩44.85 Billion ≈ $30.40 Million |
₩52.87 Billion ≈ $35.83 Million |
+54.06pp |
| 2017-12-31 | 30.79% | ₩2.27 Billion ≈ $1.54 Million |
₩7.38 Billion ≈ $5.00 Million |
+1.51pp |
| 2016-12-31 | 29.27% | ₩2.58 Billion ≈ $1.75 Million |
₩8.82 Billion ≈ $5.98 Million |
-1.40pp |
| 2015-12-31 | 30.67% | ₩3.01 Billion ≈ $2.04 Million |
₩9.80 Billion ≈ $6.64 Million |
-- |
About Biosolution Co.Ltd
Bio Solution Co.,Ltd. develops, manufactures, and sells cell therapy products worldwide. The company offers CartiLife, an autologous chondrocyte cell-based therapy for the restoration of symptomatic and structural complications caused by articular cartilage defects; KeraHeal-Allo, a thermosensitive hydrogel-type allogenic keratinocyte cell-therapy product to promote re-epithelialization of deep 2… Read more